Red Light Therapy for Fibromyalgia & Chronic Pain

Fibromyalgia is one of the most frustrating conditions in modern medicine — for patients and clinicians alike. Widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive difficulties (“fibro fog”) affect an estimated 2–4% of the population, with women diagnosed roughly seven times more often than men. Conventional treatments (pregabalin, duloxetine, amitriptyline, exercise therapy) provide incomplete relief for most patients, and many people with fibromyalgia explore complementary approaches out of necessity.

Red light therapy — more precisely, photobiomodulation (PBM) — has attracted growing interest as a non-invasive, drug-free option for fibromyalgia and chronic widespread pain. The evidence is limited but genuinely promising, and the biological mechanisms are plausible. This page provides an honest, evidence-based assessment of what we currently know.

Understanding Fibromyalgia: Why It Is So Difficult to Treat

Fibromyalgia is classified as a central sensitisation syndrome. Unlike inflammatory arthritis or structural injuries, fibromyalgia involves:

Central Sensitisation

The central nervous system amplifies pain signals. Normal sensory input — light touch, pressure, temperature changes — is processed as painful (allodynia) or as disproportionately painful (hyperalgesia). Functional MRI studies have demonstrated that fibromyalgia patients show increased activation in pain-processing brain regions in response to stimuli that healthy controls perceive as non-painful (Gracely et al., 2002, Arthritis & Rheumatism, 46(5):1333-1343).

Neuroinflammation

Emerging evidence points to glial cell activation and neuroinflammation as contributors to fibromyalgia pathophysiology. Albrecht et al. (2019) used PET imaging to demonstrate elevated markers of neuroinflammation in fibromyalgia patients, particularly in the somatosensory cortex (Brain, Behavior, and Immunity, 75:70-76). This neuroinflammatory component provides a potential target for PBM.

Peripheral Pain Generators

While fibromyalgia is primarily a central condition, many patients also have identifiable peripheral pain sources — myofascial trigger points, enthesopathies, small fibre neuropathy — that feed into and maintain the central sensitisation cycle. These peripheral components are where local PBM may have the most direct effect.

Mitochondrial Dysfunction

Several studies have reported mitochondrial abnormalities in fibromyalgia. Cordero et al. (2010) found reduced coenzyme Q10 levels and impaired mitochondrial function in skin fibroblasts from fibromyalgia patients (Clinical Biochemistry, 43(13-14):1174-1176). Given that PBM’s primary mechanism of action involves stimulating cytochrome c oxidase in the mitochondrial electron transport chain, this mitochondrial dysfunction represents a particularly relevant therapeutic target.

What the Evidence Shows

Clinical Trials

Armagan et al. (2006) conducted a randomised controlled trial of low-level laser therapy (LLLT) in fibromyalgia, published in Rheumatology International (27(1):27-31). Forty patients were randomised to active laser (830 nm, applied to tender points) or sham treatment for 3 weeks. The active laser group showed significant improvements in pain scores, morning stiffness, and number of tender points compared with the sham group. Limitations include small sample size and short follow-up.

Gur et al. (2002) studied 904 nm pulsed laser therapy in 40 fibromyalgia patients in a double-blind RCT published in Lasers in Surgery and Medicine (30(5):390-396). The treatment group received laser to bilateral cervical, thoracic, and lumbar paravertebral areas plus tender points. Significant improvements were found in pain, fatigue, morning stiffness, and tender point count compared with sham. Notably, effects were maintained at 3-week follow-up.

Ruaro et al. (2014) investigated LLLT (904 nm) for fibromyalgia in a randomised, double-blind trial published in Lasers in Medical Science (29(6):1815-1819). The active group showed significant improvements in pain intensity, number of tender points, and quality-of-life measures (Fibromyalgia Impact Questionnaire). Again, the sample size was small (20 patients per group).

da Silva et al. (2018) published a broader review of PBM for fibromyalgia in Lasers in Medical Science (33(1):173-180), concluding that PBM showed “positive effects on pain, tender point count, and quality of life” but emphasising the need for larger, well-designed trials with standardised protocols.

Systematic Reviews

Yeh et al. (2019) conducted a systematic review and meta-analysis of PBM for fibromyalgia, published in the Journal of Pain Research (12:451-459). Across nine eligible studies, PBM significantly reduced pain intensity (standardised mean difference: -1.16) and improved functional status compared with controls. The authors noted moderate heterogeneity between studies and concluded that PBM “may be an effective adjunct therapy” but called for larger, higher-quality trials.

The overall picture: Multiple small RCTs consistently show benefit. No large-scale, multi-centre trial has been conducted. The evidence is best described as “promising but preliminary” — strong enough to justify trying PBM as an adjunct therapy, but not strong enough to make definitive claims about efficacy.

How PBM May Help Fibromyalgia

Based on the established mechanisms of photobiomodulation, there are several pathways through which PBM could benefit fibromyalgia patients:

1. Peripheral Pain Reduction

PBM at therapeutic wavelengths (630–660 nm red, 800–850 nm near-infrared) reduces pain at treated sites through multiple mechanisms:

Reduced inflammatory mediators — PBM decreases prostaglandin E2, interleukin-1 beta, and tumour necrosis factor alpha at treated tissues (Hamblin, 2017, Photochemistry and Photobiology, 93(5):1199-1201)
Endorphin release — localised PBM can stimulate endorphin release in treated tissues
Nerve conduction modulation — PBM has been shown to alter nerve conduction velocity in peripheral nerves, potentially reducing pain signal transmission

2. Reduction of Trigger Points

Many fibromyalgia patients have identifiable myofascial trigger points — hyperirritable spots within taut bands of skeletal muscle. PBM applied directly to trigger points can reduce local contracture, improve microcirculation, and decrease referred pain patterns. This is the most straightforward application and the one with the most direct evidence.

3. Mitochondrial Support

If mitochondrial dysfunction is genuinely part of fibromyalgia pathophysiology, PBM’s action on cytochrome c oxidase could provide direct cellular support:

Increased ATP production
Reduced reactive oxygen species (via improved electron transport chain efficiency)
Improved cellular energy metabolism

This mechanism is speculative for fibromyalgia specifically but is well-established at the cellular level.

4. Sleep Improvement (Indirect)

Pain reduction from PBM may indirectly improve sleep quality — a critical issue in fibromyalgia where sleep disturbance both results from and perpetuates the pain cycle. Additionally, PBM applied transcranially has been shown to influence melatonin production and circadian rhythms, which could have further benefits for disordered sleep (see our neurotransmitters page for more detail).

5. Neuroinflammation Modulation

Transcranial PBM — the application of near-infrared light to the scalp — has been shown in preclinical studies to reduce glial cell activation and neuroinflammatory markers. Salehpour et al. (2018) reviewed transcranial PBM evidence in Molecular Neurobiology (55(8):6601-6636) and noted anti-neuroinflammatory effects across multiple animal models. If neuroinflammation contributes to fibromyalgia, transcranial PBM could theoretically address this central component, though human evidence for this specific application in fibromyalgia is currently absent.

Treatment Protocol for Fibromyalgia

Fibromyalgia requires a multi-site treatment approach, reflecting the widespread nature of the condition.

Wavelength Selection

660 nm (red) — for superficial tender points and trigger points
810–850 nm (near-infrared) — for deeper tissue penetration, muscle treatment, and potential transcranial application
Dual-wavelength (red + NIR) is optimal for fibromyalgia

Treatment Areas

Fibromyalgia treatment should address multiple sites per session:

Primary tender point regions:

Cervical spine and suboccipital area — treat the posterior neck from the occiput to C7. This region contains common fibromyalgia tender points and is relevant to associated headaches and cervicogenic pain
Upper trapezius (bilateral) — one of the most consistently tender regions in fibromyalgia
Supraspinatus (bilateral) — above the scapular spine
Lumbar paravertebral muscles — treat the entire lumbar spine bilaterally
Gluteal region — common trigger point and referred pain area
Lateral epicondyles and knees — if symptomatic

Optional transcranial treatment:

Apply NIR (810–850 nm) to the forehead and temporal regions for 10–15 minutes
Theoretical benefit for neuroinflammation and sleep regulation
Evidence is preclinical; include as an experimental addition rather than a core protocol

Dosing Parameters

Energy density: 4–8 J/cm² per treatment site
Power density: 30–100 mW/cm² at the skin surface (device-dependent)
Treatment time per site: 2–5 minutes (depending on device irradiance)
Total session time: 20–40 minutes (covering multiple sites)

Frequency

Initial phase (weeks 1–4): 5 sessions per week
Maintenance phase (weeks 5+): 3 sessions per week
Minimum trial period: 8 weeks before assessing response
Ongoing use: Many fibromyalgia patients report that benefits require continued treatment; this is consistent with PBM’s mechanism (supporting cellular function rather than curing an underlying disease)

Practical Considerations

Full-body panels provide the most efficient approach for fibromyalgia because they can treat multiple regions simultaneously. A large panel (such as a full-height model from Mito Red Light, PlatinumLED, or Bontanny) allows the patient to stand 15–30 cm from the panel and receive treatment to the entire posterior or anterior body surface.

Targeted wraps and pads are useful as supplements for specific tender points that need higher doses — wrap a knee pad around the knee, or a shoulder wrap over the trapezius, for concentrated treatment.

Combination with exercise: The National Institute for Health and Care Excellence (NICE) guidelines for fibromyalgia emphasise aerobic exercise as a first-line treatment. PBM may enhance exercise tolerance and reduce post-exercise pain flares, making it a useful adjunct to a graded exercise programme.

What to Realistically Expect

Based on the available evidence, here is an honest assessment of what PBM can and cannot do for fibromyalgia:

Likely Benefits

Reduction in pain intensity — most studies show a 20–40% reduction in pain scores with PBM
Decreased tender point sensitivity — consistent finding across multiple trials
Improved morning stiffness — reported in several studies
Better functional capacity — as measured by validated questionnaires (FIQ)
Reduced reliance on pain medication — some patients report reducing analgesic use (though this should be done under medical supervision)

Unlikely Benefits

Complete pain resolution — fibromyalgia is a chronic condition; no treatment eliminates it entirely
Rapid effects — most patients need 4–8 weeks of consistent treatment before meaningful improvement
Replacement for exercise and sleep hygiene — PBM works best as part of a multimodal approach, not as a standalone cure

Important Caveats

Response varies significantly between individuals. Some fibromyalgia patients report substantial benefit; others notice minimal change
Benefits typically require ongoing treatment. Unlike a course of antibiotics that eliminates an infection, PBM supports cellular function and modulates pain processing — effects that may diminish when treatment stops
The evidence base is still small. All existing trials have small sample sizes (20–40 patients) and significant methodological limitations

Fibromyalgia PBM vs Other Non-Drug Treatments

Treatment	Evidence Level	Practicality	Cost	Typical Response
Graded aerobic exercise	Strong (NICE recommended)	Moderate (requires motivation)	Free	30–50% pain reduction
CBT for chronic pain	Strong (NICE recommended)	Moderate (requires therapist)	NHS or £50–100/session	Improved coping, 20–30% pain reduction
Acupuncture	Moderate	Moderate (requires practitioner)	£40–80/session	Variable, 20–40% in responders
Photobiomodulation	Low-Moderate	High (home-based)	£100–500 (device purchase)	20–40% pain reduction in responders
Hydrotherapy	Moderate	Low (requires pool access)	Variable	20–40% pain reduction
TENS	Low-Moderate	High (home-based)	£20–50	Variable, temporary relief

PBM’s advantages for fibromyalgia are its home-based convenience, lack of side effects, and ability to be combined with every other treatment on this list. Its disadvantage is the weaker evidence base compared with exercise and psychological therapies.

Device Recommendations for Fibromyalgia

Given the multi-site nature of fibromyalgia, device selection should prioritise coverage area:

Best option: Full-body panel A large panel (60+ LEDs, full height or half height) allows treatment of the entire back, neck, and posterior body in a single standing session. This is the most time-efficient approach for a condition that requires treating many areas. Look for dual-wavelength (660 nm + 850 nm) panels from established manufacturers.

Budget option: Mid-size tabletop panel A mid-size panel (such as the Hooga HG300 or similar) can treat the neck, upper back, and lower back in sequence across a 20–30 minute session. Less efficient than a full-body panel but adequate if budget is a constraint.

Supplementary: Targeted wrap A flexible NIR wrap for specific high-pain areas (knee, shoulder) provides concentrated dosing where it is most needed. Useful as an addition to panel treatment, not as a replacement.

The Honest Assessment

Fibromyalgia is a condition where people are understandably desperate for relief, and that desperation makes them vulnerable to overblown marketing claims. Here is the unvarnished picture:

Red light therapy is not a cure for fibromyalgia. No treatment is. The evidence for PBM in fibromyalgia is encouraging — multiple small trials show consistent benefit, the mechanisms are biologically plausible, and the safety profile is excellent. But the evidence is still early-stage, and individual responses vary substantially.

What PBM offers for fibromyalgia is a safe, non-invasive addition to a multimodal treatment strategy. It works best alongside exercise, good sleep hygiene, and appropriate medical management. It has no meaningful side effects, no drug interactions, and can be used indefinitely at home without ongoing clinical costs.

If you have fibromyalgia and conventional treatments are providing incomplete relief, a trial of PBM is reasonable. Commit to at least 8 weeks of consistent use (5 sessions per week initially) before judging whether it helps you. Keep a symptom diary to track your response objectively rather than relying on general impressions.

For many fibromyalgia patients, even a 20–30% reduction in pain intensity represents a meaningful improvement in quality of life. That is a realistic expectation from PBM based on current evidence.

This article is for informational purposes only and does not constitute medical advice. Fibromyalgia management should involve a healthcare professional. If you are taking prescribed medication, do not alter your dosage based on information in this article without consulting your doctor.